# Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

> **NCT00969319** · — · COMPLETED · sponsor: **Bayer** · enrollment: 105 (actual)

## Conditions studied

- Blood Coagulation Disorders
- Hemophilia A

## Interventions

- **BIOLOGICAL:** Recombinant Factor VIII (Kogenate FS, BAY14-2222)

## Key facts

- **NCT ID:** NCT00969319
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-02
- **Final completion:** 2014-02
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00969319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00969319, "Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00969319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*